Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma.
Aged
Aged, 80 and over
Carcinoma, Pancreatic Ductal
/ mortality
Female
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Nerve Fibers
/ pathology
Pancreas
/ innervation
Pancreatic Neoplasms
/ mortality
Pancreatitis, Chronic
/ pathology
Prognosis
Pancreatic Neoplasms
ductal carcinoma
intrapancreatic neural density
intrapancreatic neural invasion
pancreas
prognosis
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
17
10
2018
revised:
12
02
2019
accepted:
13
02
2019
pubmed:
19
2
2019
medline:
17
4
2019
entrez:
19
2
2019
Statut:
ppublish
Résumé
Neural invasion is one of the malignant features contributing to locally advanced and/or metastatic disease progression in patients with pancreatic ductal adenocarcinoma (PDAC). Few studies exist on the distribution and state of nerve fibers in PDAC tissue and their clinicopathological impacts. The aim of the present study was to investigate the clinicopathological characteristics and prognostic value of intrapancreatic neural alterations in patients with PDAC. We retrospectively analyzed 256 patients with PDAC who underwent macroscopic curative surgery. Nerve fibers, immunolabeled with a specific neural marker GAP-43, were digitally counted and compared among PDAC, chronic pancreatitis (CP) and normal pancreatic tissues. Interlobular nerve fibers were apparently hypertrophic in both CP and PDAC, although intrapancreatic neural density and nerve number decreased characteristically in PDAC. They tended to decrease toward the center of the tumor. Kaplan-Meier survival analyses revealed a statistically significant correlation between low neural density and shorter overall survival (OS) (P = 0.014), and between high neural invasion and shorter OS (P = 0.017). Neural density (P = 0.04; HR = 1.496; 95% CI 1.018-2.199) and neural invasion ratio (P = 0.064; HR = 1.439; 95% CI .980-2.114) were prognostic factors of shorter OS in the multivariate analysis. These findings suggest low intrapancreatic neural density in patients with PDAC as an independent prognosticator, which may represent aggressive tumor behavior. Furthermore, we propose a simple, practical and reproducible method (to measure neural density and the neural invasion ratio during conventional histopathological diagnosis of PDAC), which has been validated using another cohort (n = 81).
Identifiants
pubmed: 30776178
doi: 10.1111/cas.13975
pmc: PMC6447831
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1491-1502Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology of Japan
Organisme : Japan Agency for Medical Research and Development
Organisme : National Cancer Center Research and Development Fund
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Oncotarget. 2016 Jan 26;7(4):4183-94
pubmed: 26716653
Cancer Sci. 2012 Oct;103(10):1756-63
pubmed: 22716017
Gut. 2007 Apr;56(4):534-44
pubmed: 17047099
Pancreas. 2016 Apr;45(4):593-600
pubmed: 26495781
Cancer Radiother. 2010 Nov;14 Suppl 1:S94-102
pubmed: 21129675
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Ann Surg. 2014 Nov;260(5):900-7; discussion 907-8
pubmed: 25379860
PLoS One. 2014 May 05;9(5):e94357
pubmed: 24797069
Islets. 2015;7(1):e1024405
pubmed: 26030186
Cancer Lett. 2018 Oct 10;434:56-69
pubmed: 29981812
Pancreatology. 2018 Jul;18(5):536-549
pubmed: 29778400
Virchows Arch. 2016 Dec;469(6):621-634
pubmed: 27709361
Semin Radiat Oncol. 2016 Oct;26(4):320-37
pubmed: 27619253
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
J Clin Oncol. 2009 Apr 10;27(11):1806-13
pubmed: 19273710
Gastroenterology. 2009 Jan;136(1):177-186.e1
pubmed: 18992743
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
J Natl Cancer Inst. 2010 Jan 20;102(2):107-18
pubmed: 20068194
Am J Gastroenterol. 2009 Oct;104(10):2555-65
pubmed: 19568227
Cancer Sci. 2019 Apr;110(4):1491-1502
pubmed: 30776178
Curr Gastroenterol Rep. 2011 Apr;13(2):131-9
pubmed: 21258973
Nat Rev Gastroenterol Hepatol. 2015 Nov;12(11):649-59
pubmed: 26460352
Cancer Res. 2014 Mar 15;74(6):1718-27
pubmed: 24448244
N Engl J Med. 2010 Apr 29;362(17):1605-17
pubmed: 20427809
Br J Cancer. 2014 Nov 11;111(10):1917-23
pubmed: 25314063
Nat Rev Cancer. 2016 Jun;16(6):399-408
pubmed: 27150016
Am J Surg Pathol. 2013 Jul;37(7):1030-8
pubmed: 23648465
Pancreas. 2011 Apr;40(3):464-8
pubmed: 21289526
Cancer Lett. 2017 Apr 28;392:83-93
pubmed: 28189533
Cancer Sci. 2015 Dec;106(12):1750-60
pubmed: 26395180
Ann Surg. 2010 May;251(5):923-31
pubmed: 20395845
Surg Oncol. 2017 Mar;26(1):105-115
pubmed: 28317579